José L. Lanciego, MD, PhD, is a Staff Scientist at the Center for Applied Medical Research (CIMA), and Associate Professor of Neurosciences at the University of Navarra Medical School. He is the leader of the Laboratory of Functional Basal Ganglia Neuroanatomy at CIMA. His recent research interests include the pathophysiology of Parkinson’s disease using non-human primate models. Ongoing work focuses on gene therapy approaches for Parkinson’s disease. He has been recognized as “Group of Excellence” in the field of Neurodegenerative Diseases by the Spanish Ministry of Health since December 2006, and helped found the “Network Center for Biomedical Research in Neurodegenerative Disorders”. In September 2019, he co-founded Handl Therapeutics B.V., a gene therapy company pushing forward the development of novel disease-modifying therapies for the treatment of Parkinson’s disease.
José Luis Lanciego, MD, PhD
Biomedical Research Networking Center on Neurodegenerative Diseases | Pamplona, Spain
José L. Lanciego, MD, PhD, is a Staff Scientist at the Center for Applied Medical Research (CIMA), and Associate Professor of Neurosciences at the University of Navarra Medical School. He is the leader of the Laboratory of Functional Basal Ganglia Neuroanatomy at CIMA. His recent research interests include the pathophysiology of Parkinson’s disease using non-human primate models. Ongoing work focuses on gene therapy approaches for Parkinson’s disease. He has been recognized as “Group of Excellence” in the field of Neurodegenerative Diseases by the Spanish Ministry of Health since December 2006, and helped found the “Network Center for Biomedical Research in Neurodegenerative Disorders”. In September 2019, he co-founded Handl Therapeutics B.V., a gene therapy company pushing forward the development of novel disease-modifying therapies for the treatment of Parkinson’s disease.
